Vertex Pharmaceuticals (VRTX) EBITDA (2009 - 2026)

Vertex Pharmaceuticals' EBITDA history runs 18 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• On a quarterly basis, EBITDA rose 80.62% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $4.7 billion, a 730.65% increase from a year earlier, with the FY2025 full-year figure at $4.2 billion, up 1891.88% from the prior year.
• EBITDA slipped to $1.1 billion in Q1 2026 per VRTX's latest filing, from $1.2 billion in the prior quarter.
• Across five years, EBITDA topped out at $1.2 billion in Q4 2025 and bottomed at -$3.5 billion in Q2 2024.
• The 5-year median for EBITDA is $1.0 billion (2022), against an average of $777.5 million.
• Across the five-year window, EBITDA surged 3019.0% in 2022 and slumped 442.43% in 2024, its largest moves.
• Year by year, EBITDA stood at $1.0 billion in 2022, then declined by 4.35% to $988.5 million in 2023, then rose by 3.79% to $1.0 billion in 2024, then grew by 17.53% to $1.2 billion in 2025, then dropped by 5.62% to $1.1 billion in 2026.
• Per Business Quant, the three latest VRTX EBITDA figures stand at $1.1 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.2 billion (Q3 2025).